|drug1752||Ivermectin Pill Wiki||0.71|
|D058345||Asymptomatic Infections NIH||0.71|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai population. Outcomes include safety and duration of detectable of SAR-CoV2 in nasopharyngeal/ throat (NP) swab by polymerase chain reaction amplification (PCR) after treatment. 40-50 patients in each treatment arm is planned, with an interim analysis when approximately 50% of cases is enrolled.
Description: Comparison of adverse event rates between treatment armsMeasure: Adverse event rates Time: after first dose until day 28 of follow up
Description: comparison of median duration for detectable SAR-CoV2 by PCR from NP swab in each armMeasure: Efficacy for shortening duration of SAR-CoV2 detection by PCR Time: weekly after treatment until 4th week
Description: comparison of median duration for total antibody detection in each armMeasure: Antibody detection rates Time: weekly after treatment until 4th week
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports